Biotechnology - Techseriesinsight

November 28, 2024
Business Wire
Biotechnology

Dr. Reddy’s launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), announced the launch of Toripalimab in India....

November 28, 2024
PRNewswire
Biotechnology

Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain

Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW) announced that the company has entered into an exclusive licensing agreement with Medvisis Switzerland AG (“Medvisis”) in Switzerland and Liechtenstein, for exclusive rights to the commercialization of...

November 28, 2024
PRNewswire
Biotechnology

New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the new indication...

November 28, 2024
PRNewswire
Biotechnology

Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China’s National Reimbursement Drug List

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and...

November 27, 2024
PRNewswire
Biotechnology

Source Agriculture Corp. Makes Strategic Investment in Ascribe Bioscience to Advance Sustainable Crop Protection Solutions

Source Agriculture Corp., an innovative agri-tech investments, is pleased to announce a strategic investment in Ascribe Bioscience, a cutting-edge company dedicated to developing sustainable crop protection solutions. Ascribe, founded...

November 27, 2024
PRNewswire
Biotechnology

Soccer Heading Damages Brain Regions Affected in CTE

Soccer heading may cause more damage to the brain than previously thought, according to a study being presented next week at the annual meeting of the Radiological Society of North America (RSNA). Heading...

November 26, 2024
Business Wire
Biotechnology

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through...

November 25, 2024
PRNewswire
Biotechnology

J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment ‘JIN-001’ – Enhancing Radiation and Chemotherapy Efficacy

J INTS BIO announced research findings on its innovative brain tumor treatment, ‘JIN-001,’ developed in collaboration with MD Anderson Cancer Center, at the 2024 Society of Neuro-Oncology (SNO) Annual Meeting in Texas,...

November 22, 2024
PRNewswire
Biotechnology

FDA Granted Orphan Drug Designation of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs, for Treatment of Neuroendocrine Cancer

Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as “Leads Biolabs”) announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by the company with global intellectual property rights for...

November 21, 2024
PRNewswire
Biotechnology

Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans

Vicebio Ltd (“Vicebio”), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory viruses, today announces its progress in the ongoing VXB-241 bivalent RSV-hMPV Phase 1 (P1) study as well as...